Lawsuit alleges no warnings or information was provided about the risk of hearing damage from Tepezza, which could have been avoided with medical monitoring
Horizon Pharmaceuticals claims the Tepezza hearing loss lawsuit is preempted by federal law because the manufacturer would have been unlikely to change the label warnings without FDA permission.
Horizon has objected to the call to consolidate Tepezza hearing loss lawsuits, claiming the cases will be too different to benefit from pretrial coordination.
Plaintiffs say Horizon has failed to share key financial projections to shareholders of what will likely happen if Amgen buys Tepezza manufacturer Horizon Therapeutics
Amgen agreed to buy Horizon as it faces unknown liability from Tepezza lawsuits over hearing loss suffered by users of the thyroid eye disease drug
Hyperglycemia caused by the side effects of Tepezza may persist after use of the medication has stopped, researchers warn
Researchers have yet to investigate whether multiple courses increases the risk of Tepezza hearing loss side effects identified in other studies and case reports
Lawsuit alleges that the warnings about potential Tepezza hearing loss side effects misled users and doctors, suggesting that the problems were temporary. However, users are reporting irreversible hearing loss caused by Tepezza
Researchers linked Tepezza and ear toxicity, which led to permanent hearing problems for patients, some of which needed hearing aids
Plaintiff claims that warnings about Tepezza hearing problems were withheld by drug maker, leading users to experience tinnitus and permanent hearing loss
